JPWO2020006557A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006557A5 JPWO2020006557A5 JP2020572891A JP2020572891A JPWO2020006557A5 JP WO2020006557 A5 JPWO2020006557 A5 JP WO2020006557A5 JP 2020572891 A JP2020572891 A JP 2020572891A JP 2020572891 A JP2020572891 A JP 2020572891A JP WO2020006557 A5 JPWO2020006557 A5 JP WO2020006557A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- group
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- -1 C 6 alkyl benzene Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- 150000004996 alkyl benzenes Chemical class 0.000 claims 4
- 125000000262 haloalkenyl group Chemical group 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100038248 Cis-aconitate decarboxylase Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101001032339 Homo sapiens Cis-aconitate decarboxylase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862763735P | 2018-06-29 | 2018-06-29 | |
| US62/763,735 | 2018-06-29 | ||
| PCT/US2019/040121 WO2020006557A1 (en) | 2018-06-29 | 2019-07-01 | Compositions and methods of using itaconic acid derivatives |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529752A JP2021529752A (ja) | 2021-11-04 |
| JP2021529752A5 JP2021529752A5 (https=) | 2022-06-21 |
| JPWO2020006557A5 true JPWO2020006557A5 (https=) | 2022-06-21 |
| JP7396682B2 JP7396682B2 (ja) | 2023-12-12 |
Family
ID=68985877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572891A Active JP7396682B2 (ja) | 2018-06-29 | 2019-07-01 | イタコン酸誘導体の組成物及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12060310B2 (https=) |
| EP (1) | EP3813815B1 (https=) |
| JP (1) | JP7396682B2 (https=) |
| ES (1) | ES3063485T3 (https=) |
| WO (1) | WO2020006557A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55795A (fr) | 2019-04-30 | 2022-03-09 | Sitryx Therapeutics Ltd | Dérivés d'acide itaconique et leurs utilisations dans le traitement d'une maladie inflammatoire ou d'une maladie associée à une réponse immunitaire indésirable |
| EP4237404A1 (en) * | 2020-10-29 | 2023-09-06 | Sitryx Therapeutics Limited | Novel compounds |
| EP4326247A1 (en) | 2021-04-23 | 2024-02-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Citraconic acid and derivatives thereof for use as a medicament |
| CN119685257B (zh) * | 2024-12-16 | 2026-02-27 | 华中科技大学同济医学院附属协和医院 | 体外诱导t细胞免疫记忆分化的方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260479A (en) * | 1991-12-16 | 1993-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| EP1062954B1 (en) * | 1998-10-27 | 2007-05-30 | Suntory Limited | Use of itaconic acid for regulation of glycolytic metabolism |
| EP2480531B1 (en) * | 2009-09-21 | 2014-11-05 | ChemoCentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators |
| LU91877B1 (en) * | 2011-09-23 | 2013-03-25 | Univ Luxembourg | Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy |
| US8691993B2 (en) * | 2011-12-12 | 2014-04-08 | Hoffmann-La Roche Inc. | Piperidinyl naphthylacetic acids |
| JP2015516965A (ja) * | 2012-04-03 | 2015-06-18 | アポセンス リミテッドＡｐｏｓｅｎｓｅ Ｌｔｄ． | 診断指標及び治療指標のための新規な標的指向性薬剤 |
| EP3416634A4 (en) * | 2016-02-15 | 2019-10-09 | Artyomov, Maxim | IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF |
-
2019
- 2019-07-01 ES ES19826034T patent/ES3063485T3/es active Active
- 2019-07-01 JP JP2020572891A patent/JP7396682B2/ja active Active
- 2019-07-01 EP EP19826034.1A patent/EP3813815B1/en active Active
- 2019-07-01 US US17/255,150 patent/US12060310B2/en active Active
- 2019-07-01 WO PCT/US2019/040121 patent/WO2020006557A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534124A5 (https=) | ||
| JP2012529535A5 (https=) | ||
| JP2011530500A5 (https=) | ||
| RU2010106393A (ru) | Новые микробиоциды | |
| CA3105662C (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
| JP2004523561A5 (https=) | ||
| CA2439410A1 (en) | Analogs of thalidomide as potential angiogenesis inhibitors | |
| AR123355A1 (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| CA2565599A1 (en) | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors | |
| JP2021529752A5 (https=) | ||
| JP2003519676A5 (https=) | ||
| JP2007529479A (ja) | マラリアの治療及び予防を意図する医薬品を調製するためのインダゾールカルボキサミド誘導体の使用 | |
| JP2007507542A5 (https=) | ||
| RU2016139352A (ru) | Способ получения [(3-гидроксипиридин-2-карбонил)амино]алкановых кислот, сложных эфиров и амидов | |
| JP2018511647A5 (https=) | ||
| CA2684105A1 (en) | Pyridine derivatives | |
| AR074024A1 (es) | Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| AR050364A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2021512889A5 (https=) | ||
| RU2371433C2 (ru) | Фенилзамещенные пирролидоны | |
| JP2004525183A5 (https=) | ||
| AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
| AR072611A1 (es) | Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne. |